Lumicks

About Lumicks

LUMICKS is a life science tools company that develops and commercializes instruments for dynamic single-molecule and cell avidity analysis, enabling academic and biopharma researchers to get a deeper understanding of the fundamental mechanisms of biology and the drivers of disease. The company was established in 2014 as a spin-off from the Vrije Universiteit (VU) Amsterdam, founded by Olivier Heyning, Andrea Candelli, and Gijs Wuite. The founders' backgrounds are deeply rooted in biophysics; Gijs Wuite is a professor and head of the physics of living systems department at VU Amsterdam, while Olivier Heyning and Andrea Candelli both hold PhDs in the field, bringing a wealth of scientific and business development experience to the venture.

The company's core business revolves around providing sophisticated instruments that allow researchers to analyze complex biological interactions in real-time. These tools are built upon Nobel Prize-winning technologies, specifically optical tweezers and super-resolution microscopy. This technological foundation allows LUMICKS' products to measure the forces and interactions between single molecules and cells, a capability that bridges the gap between structural biology and functional outcomes. The company's flagship products include the C-Trap®, which integrates optical tweezers with microfluidics and fluorescence microscopy, and the z-Movi®, a cell avidity analyzer. These instruments serve a client base that includes top universities, research institutes, and leading pharmaceutical and biotechnology companies. The business model is based on the sale of these high-value instruments and associated consumables, as well as providing support and services.

LUMICKS' technology provides direct, real-time analysis of biological mechanisms, which is a significant advantage in fields like immuno-oncology, immunology, and genetic editing. For instance, the z-Movi® instrument can measure the binding strength (avidity) between immune cells and cancer cells, providing crucial insights for the development of new immunotherapies. This allows researchers to directly link a molecule's structure to its function at a granular level. The company has achieved significant milestones, including a major financing round of $93 million in 2021 to accelerate its commercial expansion, particularly in the immuno-oncology and drug development markets. This funding has supported the scaling of its operations and the expansion of its product portfolio, solidifying its position in the life sciences and diagnostics market.